高危局限前列腺癌SBRT长期随访:SHARP联盟440例更新分析
SHARP联盟汇总10项前瞻性研究440例高危局限前列腺癌患者,中位随访60.4个月,5年生化复发率和远处转移率分别为22%和9.2%。接受强化治疗(≥12个月ADT联合≥8 Gy/分次SBRT)者5年生化复发率和远处转移率分别为7.4%和3.7%,强化治疗与生化复发和远处转移风险显著降低相关。
要点
- 高危局限前列腺癌SBRT长期安全有效,5年生化复发率22%、远处转移率9.2%。
- 强化治疗(≥12个月ADT联合≥8 Gy/分次SBRT)与生化复发和远处转移风险显著降低相关。
- 5年≥2级泌尿生殖毒性和胃肠道毒性分别为23%和10%。
核心结论
- 高危局限前列腺癌SBRT长期随访安全有效,应纳入治疗共同决策。
研究设计与样本
- SHARP联盟汇总9家机构10项前瞻性临床研究的个体患者数据,共440例高危局限前列腺癌患者。
- 采用Kaplan-Meier法估计5年生化复发和远处转移,按是否接受强化治疗分层。
- 采用多变量Cox比例风险模型评估强化治疗对生化复发无生存和远处转移无生存的影响。
- 晚期≥2级胃肠道和泌尿生殖毒性采用时间至事件模型分析。
主要发现
- 中位随访60.4个月,440例患者5年生化复发率为22%(95%CI=17-26%),远处转移率为9.2%(95%CI=6.2-12%)。
- 93例(21%)接受强化治疗者5年生化复发率为7.4%(95%CI=1.7-13%),远处转移率为3.7%(95%CI=0-7.9%)。
- 强化治疗与生化复发风险降低显著相关(HR=0.38,95%CI=0.20-0.74,p=0.005)。
- 强化治疗与远处转移风险降低显著相关(HR=0.43,95%CI=0.18-0.99,p=0.049)。
- 总体队列5年≥2级泌尿生殖毒性率为23%(95%CI=19-27%),胃肠道毒性率为10%(95%CI=7-13%)。
关键数值与推荐
- 强化治疗定义为≥12个月雄激素剥夺治疗联合极度剂量递增(≥8 Gy/分次)前列腺定向SBRT。
临床怎么用
- 高危局限前列腺癌患者选择SBRT时,应考虑联合≥12个月ADT和≥8 Gy/分次剂量以强化治疗。
- SBRT长期毒副作用可接受,应与患者共同决策治疗选择。
局限性
- 治疗技术存在异质性。
- 研究为非随机性质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Most patients with high-risk localized prostate cancer (HRLPC) do not undergo stereotactic body radiotherapy (SBRT) in part because of the limited evidence of long-term outcomes. We report long-term efficacy and toxicity outcomes for men treated with SBRT for HRLPC. METHODS: Individual patient data from ten prospective clinical studies evaluating SBRT for HRLPC across nine institutions were pooled in the Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate consortium. The Kaplan-Meier method was used to estimate 5-yr biochemical recurrence (BCR) and distant metastasis (DM), stratified by receipt of intensified treatment (≥12 mo of androgen deprivation therapy [ADT] with extremely dose-escalated [≥8 Gy/fraction] prostate-directed SBRT). The impact of intensified treatment on BCR-free survival and DM-free survival was evaluated using multivariable Cox proportional hazards models. Late Common Terminology Criteria for Adverse Events grade ≥2 gastrointestinal (GI) and genitourinary (GU) toxicity was analyzed using time-to-event models. KEY FINDINGS AND LIMITATIONS: In 440 patients with a median follow-up time of 60.4 mo, 5-yr BCR and DM rates were 22% (95% confidence interval [CI] = 17-26%] and 9.2% (95% CI = 6.2-12%), respectively. In the 93 patients (21%) who received intensified treatment, 5-yr BCR and DM rates were 7.4% (95% CI = 1.7-13%) and 3.7% (95% CI = 0-7.9%), respectively. Receipt of intensified therapy was associated with a significant reduction in both BCR (hazard ratio [HR] = 0.38 [95% CI = 0.20-0.74], p = 0.005) and DM (HR = 0.43 [95% CI = 0.18-0.99], p = 0.049). For the overall cohort, 5-yr rates of grade ≥2 GU and GI toxicity were 23% (95% CI = 19-27%) and 10% (95% CI = 7-13%), respectively. Limitations include heterogeneous treatment techniques and the nonrandomized nature of the study. CONCLUSIONS AND CLINICAL IMPLICATIONS: The safety and efficacy profile of SBRT for HRLPC remains favorable at long-term follow-up, and SBRT should be integrated into shared decision-making for treatment of HRLPC.
引用
- Valle LF, Romero-Kalbasi T, Jiang T, et al. Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients. Eur Urol Oncol. 2026. PMID: 41966956. doi:10.1016/j.euo.2026.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。